We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 20 of 204 for:    Oral Cancer | Recruiting Studies | NIH

The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03233724
Recruitment Status : Recruiting
First Posted : July 31, 2017
Last Update Posted : March 16, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 1, 2018
  Estimated Study Completion Date : April 15, 2020